SER-109 for Recurrent Clostridioides difficile Infection. Reply
N Engl J Med
.
2022 May 19;386(20):1957-1958.
doi: 10.1056/NEJMc2202493.
Authors
Paul Feuerstadt
1
,
Barbara H McGovern
2
Affiliations
1
Yale University School of Medicine, Hamden, CT.
2
Seres Therapeutics, Cambridge, MA bmcgovern@serestherapeutics.com.
PMID:
35584165
DOI:
10.1056/NEJMc2202493
No abstract available
Publication types
Letter
Comment
MeSH terms
Clostridioides difficile*
Clostridium Infections* / therapy
Humans
Microbiota*